cis-ACCP

• UNSPSC Description:

  cis-ACCP is an orally active antimetastatic matrix metalloproteinase-2 (MMP-2) selective inhibitor. cis-ACCP can inhibit MMP-2 and MMP-9 with IC50 values of 4 μM and 20 μM, respectively. cis-ACCP can be used for the research of a variety of chronic diseases[1].

• Target Antigen:

  MMP

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/cis-accp.html

• Purity:

  97.0

• Solubility:

  H2O : 25 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  OP(O)(C(N[C@H]1[C@@H](N)CCCC1)=O)=O

• Molecular Weight:

  222.18

• References & Citations:

  [1]Hoffman, Amnon et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. Journal of medicinal chemistry vol. 51,5 (2008): 1406-14.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  777075-44-2